All therapiesEvidence snapshot 2026-10-16
Weight & glucose

VK2735

Activates both GLP-1 and GIP receptors; the same compound is being studied as an injection and an oral tablet.

GLP-1s & metabolic therapies

At a glance

Selected evidence in this atlas
Studied use & population

Adults with obesity or overweight and comorbidity, without diabetes

Study context
Approval & development

Investigational; phase 3 VANQUISH underway

Status & indications
Selected efficacy evidence

14.7% reported weight loss · 1.7% loss with placebo · 13 weeks

VENTURE · Phase 2 · peer-reviewed · 15 mg once weekly · Assuming continued treatment

Evidence & limitations
Important safety context

Mainly GI adverse events, declining with continued dosing; 8.5% discontinued treatment for adverse events overall.

Safety context
Next milestone

A next milestone is not summarized for this therapy.

Milestone details

Study results apply to their own population, dose and analysis. They do not establish a ranking between therapies.

Evidence in the atlas

2 results

Each result belongs to its own study population, dose and analysis. Open a result for its chart, comparator, safety findings and limitations.

Weight loss

VENTURE-Oral

12.2% reported weight loss · 1.3% loss with placebo · 13 weeks

120 mg once daily after 6-week escalation

Adults with obesity or overweight and comorbidity, without diabetes

LS means from MMRM in efficacy population (39 in 120 mg arm); release does not specify intercurrent-event handling. Investigational; phase 3 planning

Safety context

GI events mostly mild/moderate; 120 mg treatment discontinuation 38%, versus 18% placebo.

Limitations: Short study; exact estimand unspecified. Total N includes exploratory maintenance arm.

Explore result Compare study Positive Top-Line Results from Phase 2 VENTURE-Oral · 2025-08-19
Weight loss

VENTURE

14.7% reported weight loss · 1.7% loss with placebo · 13 weeks

15 mg once weekly

Adults with obesity or overweight and comorbidity, without diabetes

mITT MMRM; assessments after treatment discontinuation plus 9 days set missing. Not treatment-policy. Investigational; phase 3 VANQUISH underway

Safety context

Mainly GI adverse events, declining with continued dosing; 8.5% discontinued treatment for adverse events overall.

Limitations: Short dose-finding trial; 174 in efficacy population. Headline 13.1% is placebo-adjusted, not absolute.

Explore result Compare study Weekly Subcutaneous VK2735: Phase 2 Randomized 13-Week VENTURE Study · 2026-01-08

Biology & identity

Status in this atlas: Investigational; phase 3 VANQUISH underway

Hormone activity

GLP-1Activates receptorsGIPActivates receptors

Activates both GLP-1 and GIP receptors; the same compound is being studied as an injection and an oral tablet.

What do these hormones do? GLP-1 · GIP

Investigational; no approved trade name identified as of 2026-09-13. Oral VK2735 and subcutaneous VK2735 are formulations of one compound, not separate brands.

Viking Therapeutics · Owner and developer of the wholly owned compound in subcutaneous and oral formulations.

Uses, doses and availability depend on the formulation, indication and country. Study doses below describe research; they are not prescribing instructions.

The molecule

Activates both GLP-1 and GIP receptors; the same compound is being studied as an injection and an oral tablet.
Structure not yet verified

Structure not verified

Activates both GLP-1 and GIP receptors; the same compound is being studied as an injection and an oral tablet.

Shown: Peptide drug

An exact-drug structure was not verified in this review. The named PubChem lookup did not return a compound record; no related hormone or analogue is substituted.

VK2735

Development timeline

Next milestone

A next milestone is not summarized for this therapy. This does not mean development has ended.

Development history6 selected milestones

VK2735 · compound history across indications

Selected milestones only. Earlier studies may be missing; the first listed date should not be interpreted as the start of development.

  1. VANQUISH phase 3 initiated

    Viking initiated subcutaneous VANQUISH-1 and VANQUISH-2 in adults without and with type 2 diabetes, respectively.

    Source

  2. Oral phase 2 results

    Viking reported results from the 13-week VENTURE-Oral trial of its tablet formulation.

    Source

  3. Both injectable phase 3 trials enrolled

    Viking confirmed VANQUISH-1 and VANQUISH-2 were fully enrolled; oral phase 3 was still in preparation.

    Source
  4. Announcement

    VK2735 reports results for less frequent maintenance dosing

    Following 21 weeks of weekly induction, every-other-week and monthly injections preserved more of the initial weight loss over 12 weeks than withdrawal to placebo. Sponsor-only exploratory weight endpoint, small selected maintenance cohorts and short follow-up; retention is not percentage body-weight loss. Highest monthly arm excluded an outlier; including it changes that arm's retention from 85% to 99%. No confidence intervals or verified NCT match recovered.

    Source
  5. Announcement

    Oral VK2735 registers the SUNRISE phase 3 trials

    SUNRISE-1/2 register separate phase 3 oral trials without and with type 2 diabetes, each 560 planned participants. Both are not yet recruiting, with October 15/16 estimated starts. Registration is not first dosing; injectable VANQUISH trials remain separate.

    Source
  6. Announcement

    Viking announces SUNRISE initiation; first treatment remains unverified

    SUNRISE advances beyond registration, while both live protocols still list recruitment pending and November starts. A maintenance-dosing wording error is explicitly corrected. November 2026 estimated SUNRISE starts; primary completion July/October 2028. Separate maintenance Part 2 results forecast in 2027.

    Source

Selected sources checked Oct 16, 2026. This is not an exhaustive history.